Literature DB >> 3556384

Cadralazine did not produce the SLE-syndrome when hydralazine did.

O K Andersson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3556384     DOI： 10.1007/BF00541309

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

1.  Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.

Authors:  M Catalano; J Parini; M Romano; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  [3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes].

Authors:  F Parravicini; G Scarpitta; L Dorigotti; G Pifferi
Journal:  Farmaco Sci       Date:  1979-04
  2 in total
  4 in total

1.  Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine.

Authors:  H Mulder
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.

Authors:  S Caponnetto; E Valvo; P Mocarelli; D Alberti; S Savonitto
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Inhibition of complement components C3 and C4 by cadralazine and its active metabolite.

Authors:  M Andersson; A Hanson; G Englund; B Dahlbäck
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.